We are seeking patients for an ongoing phase 3 study of a new, oral diabetes medication. The study medication is Sotagliflozin. This medication helps lower blood sugar by increasing its elimination through the kidneys and decreasing its absorption in the digestive tract. A comparison medication in the trial is glimepiride, a well-known diabetes medication.
To qualify for the study, patients must be ONLY taking metformin as their current diabetes medication. The study will last 13 months. Patients who qualify for the study will receive free study medication and all study related cares, and will be paid for each completed visit.
To learn more and to see if you qualify please contact Karrie or Jessica at (319) 272-2536 or email us at email@example.com or firstname.lastname@example.org